Table 1 |
|||
|
Patient demographics and mean doses of rituximab received by patients with various autoimmune diseases |
|||
|
Diagnosis |
Patients, n (%) |
Total observation time, patient-years |
Mean (SD) rituximab dose, mg |
|
|
|||
|
Total |
370 |
299 |
2,440 (1,295) |
|
Arthritis (non-RA)/ankylosing spondylitis/psoriatic arthritis |
6 (1.6) |
3.8 |
2,333 (816) |
|
Autoimmune haemolytic anaemia |
3 (0.8) |
1.6 |
2,233 (204) |
|
Autoimmune thrombocytopenia |
10 (2.7) |
6.5 |
2,602 (1,047) |
|
Glomerulonephritis |
9 (2.4) |
7.0 |
2,150 (1,660) |
|
Cryoglobulinaemic vasculitis |
5 (1.4) |
4.1 |
2,576 (971) |
|
Wegener's granulomatosis/microscopic polyangiitis |
58 (15.7) |
61.4 |
3,008 (1,524) |
|
Multiple sclerosis/neuromyelitis optica |
56 (15.1) |
48.3 |
2,679 (1,252) |
|
Myasthenia gravis |
5 (1.4) |
2.7 |
1,890 (1,107) |
|
Pemphigus |
37 (10.0) |
22.7 |
1,755 (1,163) |
|
Sjögren's syndrome |
6 (1.6) |
4.3 |
2,271 (995) |
|
Polydermatomyositis |
26 (7.0) |
23.4 |
2,634 (1,810) |
|
Systemic lupus erythematosus |
85 (23.0) |
66.8 |
2,331 (1,033) |
|
Vasculitis |
13 (3.5) |
9.5 |
2,277 (1,168) |
|
Overlap syndromes: mixed connective tissue disease |
19 (5.1) |
16.3 |
2,550 (1,031) |
|
Othersa |
32 (8.6) |
20.8 |
2,079 (1,224) |
|
|
|||
|
RA, rheumatoid arthritis; SD, standard deviation. aOther autoimmune diseases included: Felty syndrome (n = 1); antiphospholipid syndrome (n = 1); chronic inflammatory demyelinating polyneuropathy (CIDP) (n = 3); anti-myelin associated glycoprotein associated with CIDP (n = 1); anti-Scl70-positive systemic sclerosis with myositis (n = 1); thrombotic thrombocytopenic purpura (n = 2); epidermolysis bullosa acquisita (n = 3); bullous pemphigoid (n = 1); mucous membrane pemphigoid (n = 1); uveitis (n = 1); Behçet disease (n = 1); systemic sclerosis (n = 1); systemic sclerosis with CREST syndrome (n = 1); diffuse cutaneous sclerosis (n = 1); common variable immunodeficiency (n = 1); Castleman's disease (n = 1); human immunodeficiency virus and myopathy (n = 1); Still's disease (n = 1); Crohn's disease (n = 1); Lambert-Eaton myasthenic syndrome (n = 1); autoimmune neuropathy (n = 1); stiff-person syndrome (n = 1); unspecified vasculitis (n = 1); anti-Hu positive encephalopathy of the brain stem (n = 1); acquired factor VIII haemophilia (n = 1); sarcoidosis (n = 1); diagnosis not specified (n = 1). |
|||
|
Tony et al. Arthritis Research & Therapy 2011 13:R75 doi:10.1186/ar3337 |
|||
